Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,808JPY
20 Jul 2018
Change (% chg)

¥0 (+0.03%)
Prev Close
¥1,808
Open
¥1,817
Day's High
¥1,827
Day's Low
¥1,794
Volume
5,857,500
Avg. Vol
7,571,683
52-wk High
¥1,835
52-wk Low
¥1,336

Latest Key Developments (Source: Significant Developments)

Astellas Says To Cut 600 Jobs Via Early Retirement Programme As Part Of Japan Operations Restructuring
Monday, 21 May 2018 11:09pm EDT 

May 22 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS SAYS TO CUT 600 JOBS VIA EARLY RETIREMENT PROGRAMME AS PART OF JAPAN OPERATIONS RESTRUCTURING.  Full Article

Astellas Pharma to retire treasury shares
Wednesday, 25 Apr 2018 11:06pm EDT 

April 26 (Reuters) - Astellas Pharma Inc <4503.T>:Says it will retire 89 million shares(4.3 percent stake) of its common stock on May 31 .Says the total shares outstanding is 1.98 billion shares after the retirement .  Full Article

U.S. FDA Grants Priority Review For Supplemental New Drug Application For Xtandi
Monday, 19 Mar 2018 04:15pm EDT 

March 19 (Reuters) - Astellas Pharma Inc <4503.T>::U.S. FDA GRANTS PRIORITY REVIEW FOR A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR XTANDI® (ENZALUTAMIDE) IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).ASTELLAS PHARMA INC - ‍PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE ASSIGNED BY FDA IS JULY 2018​.  Full Article

Astellas acquires Universal Cells Inc
Tuesday, 13 Feb 2018 08:00pm EST 

Feb 13 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS ACQUIRES UNIVERSAL CELLS, INC..ASTELLAS WILL PAY UP TO $102.5 MILLION OF UPFRONT AND MILESTONES TO ACQUIRE 100 PERCENT OWNERSHIP OF UNIVERSAL CELLS.‍IMPACT OF TRANSACTION ON ASTELLAS' FINANCIAL RESULTS FOR FISCAL YEAR ENDING MARCH 31, 2018 WILL BE IMMATERIAL​.  Full Article

Astellas Pharma says top-line results for two phase 3 trials of Peficitinib in rheumatoid arthritis patients
Wednesday, 7 Feb 2018 08:40pm EST 

Feb 8 (Reuters) - Astellas Pharma Inc <4503.T>:Says it announced that the results of two phase 3 trials (RAJ3 and RAJ4 trials) on Peficitinib hydrobromide, an oral JAK inhibitor developed by the co, in rheumatoid arthritis patients with an inadequate response to existing therapy, demonstrated superiority over placebo regarding the two trials' primary endpoints.The safety analysis of these trial appears consistent with the safety profile of Peficitinib in previous clinical trials and no new safety signal was observed.  Full Article

Astellas Pharma to repurchase up to 2.1 pct shares
Tuesday, 30 Jan 2018 10:17pm EST 

Jan 31 (Reuters) - Astellas Pharma Inc <4503.T>:Says it will repurchase up to 42 million shares, representing 2.1 percent of outstanding.Says share repurchase price at up to 60 billion yen in total.Says repurchase period from Feb. 1 to March 23 .  Full Article

Astellas Says Cytomegalovirus Vaccine (ASP0113) Did Not Meet Its Primary Or Secondary Endpoints In Phase 3 Helios Clinical Trial​
Monday, 22 Jan 2018 03:00am EST 

Jan 22 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS AND VICAL ANNOUNCE TOP-LINE RESULTS FOR PHASE 3 TRIAL OF CYTOMEGALOVIRUS VACCINE ASP0113 IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS.ASTELLAS PHARMA INC SAYS ‍VACCINE WAS GENERALLY WELL TOLERATED, WITH INJECTION-SITE REACTIONS BEING MOST COMMONLY REPORTED ADVERSE EVENT​.ASTELLAS PHARMA - ASP0113 DID NOT MEET ITS PRIMARY OR SECONDARY ENDPOINTS IN PHASE 3 HELIOS CLINICAL TRIAL​.  Full Article

Astellas Pharma says application of marketing approval for blinatumomab in Japan
Monday, 8 Jan 2018 08:35pm EST 

Jan 9 (Reuters) - Astellas Pharma Inc <4503.T>:Says it announced that an application was submitted in Japan for the marketing authorization for bispecific CD19-directed CD3 T cell engager (BiTE®) antibody construct blinatumomab to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia.In Japan, blinatumomab is jointly developed by Amgen Astellas BioPharma and the co.  Full Article

Astellas acquires Mitobridge under existing collaboration
Thursday, 30 Nov 2017 07:00pm EST 

Nov 30 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS ACQUIRES MITOBRIDGE UNDER EXISTING COLLABORATION.SAYS ‍MITOBRIDGE WILL BECOME A WHOLLY-OWNED SUBSIDIARY OF ASTELLAS FOLLOWING CLOSE OF ACQUISITION​.  Full Article

Seattle Genetics, Astellas initiate phase 1b trial for Enfortumab Vedotin
Wednesday, 8 Nov 2017 08:00am EST 

Nov 8 (Reuters) - Seattle Genetics Inc :Seattle Genetics and Astellas initiate phase 1B trial of Enfortumab Vedotin in combination with immune checkpoint inhibitor therapies in locally advanced or metastatic urothelial cancer.Primary objective of trial is to assess safety and tolerability of Enfortumab Vedotin in combination with CPI therapy​.  Full Article

BRIEF- Astellas Pharma signs exclusive licensing agreement with Aquinox Pharmaceuticals

* Says it signed an exclusive license agreement with Aquinox Pharmaceuticals, Inc for Japan and certain other countries in the Asia-Pacific region for Astellas to develop and commercialize rosiptor, Aquinox’s lead drug candidate, a first-in-class, once-daily oral treatment currently in Phase 3 clinical development for interstitial cystitis/bladder pain syndrome (IC/BPS) in North America and Europe